RxDoctor Payments Data

Christine Balt

Family · Indianapolis, INNPI 1093773020

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,440 of the $29,778 with a category attached, or 72.0%. Gilead accounts for 93.6% of it on its own, with 4 other manufacturers making up the rest. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,778in general payments, 2019–2025

Across 63 payments — averaging $472.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$28K
  • Theratechnologies Inc.$2K
  • Viiv Healthcare Company$320
  • Janssen Products, LP$60
  • Johnson & Johnson$28

What the payments were for

  • Consulting fees$1,5005%
  • Speaking & faculty fees$21,44072%
  • Travel & lodging$4,39215%
  • Food & beverage$2,3588%
  • Education$880%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,778 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$4,505
Medicare patients
33
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala337$1,303,024
DovatoDolutegravir Sodium/Lamivudine79$239,907
TivicayDolutegravir Sodium89$197,894
DescovyEmtricitabine/Tenofov Alafenam75$165,890
RukobiaFostemsavir Tromethamine12$123,261
JulucaDolutegravir/Rilpivirine21$82,992
PrezcobixDarunavir/Cobicistat31$71,987
PifeltroDoravirine36$59,618
EdurantRilpivirine Hcl21$27,512
OxycontinOxycodone Hcl13$22,807
Maraviroc14$19,740
Etravirine11$11,986
MyrbetriqMirabegron14$8,329
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen83$4,918
Testosterone13$4,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$27,869$1,468,914412 claims
Viiv Healthcare CompanyDovato, Tivicay, Rukobia, Juluca$320$644,054201 claims
Johnson & JohnsonPrezcobix$28$71,98731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →